AR and prostate carcinoma: Low levels or complete loss of AR also coincided with reduced 4EBP1 expression in AR-low/null human AR program-independent prostate cancer cell line and metastatic castration-resistant PC (CRPC) LuCaP patient-derived xenografts (PDXs).